Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease
Authors' conclusion
Finerenone consistently reduced morbidity and mortality in individuals with T2D across a broad range of glycemia and glucose-lowering regimens.
Study context
- Population
- Participants with T2D and available baseline HbA1c, with chronic kidney disease (CKD) or heart failure (HF) with mildly reduced or preserved ejection fraction; mean age 66 ± 10 years, 32% women, mean HbA1c 7.6 ± 1.4%of 18,991 FINE-HEART
- Participants
- 15,365 participants
- Comparison
- Finerenone vs placebo
- Outcome
- Cardiovascular death, by baseline HbA1c and GLT regimen
- Follow-up
- Median 2.9 years
Methodological detailsFINE-HEART, placebo-controlled, subgroup analysis by baseline HbA1c and glucose-lowering therapy (GLT) regimen
- FINE-HEART
- Placebo-controlled
- Subgroup analysis by baseline HbA1c and GLT regimen
Pooled result
As reported in the abstract
Cardiovascular death: treatment effect across subgroups
- Finerenone vs Placebo: P for interaction = 0.75
- Finerenone vs Placebo: P for interaction = 0.46
Further pooled results
Kidney composite, HF hospitalization, MACE, all-cause mortality
- Finerenone consistently reduced these outcomes irrespective of baseline HbA1c and GLT regimen
Treatment effects by number of background GLTs and concomitant SGLT2i or GLP-1 RA
- Treatment effects consistent across number of background GLTs and irrespective of concomitant SGLT2i or GLP-1 RA
Original publication
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease. Diabetes Care. Published 28 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →